- Home
- ACLX vs PRCT Comparison
ACLX vs PRCT Comparison
Compare ACLX & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACLX | PRCT |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 1.5B |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACLX | PRCT |
|---|---|---|
| Price | $114.80 | $25.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $115.85 | $35.44 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | N/A | ★ N/A |
| Revenue | $22,286,000.00 | ★ $308,054,000.00 |
| Revenue This Year | $397.53 | $31.62 |
| Revenue Next Year | $123.06 | $24.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $47.86 | $19.35 |
| 52 Week High | $114.91 | $64.89 |
Technical Indicators
Market Signals| Indicator | ACLX | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 81.70 | 45.05 |
| Support Level | $66.06 | $19.35 |
| Resistance Level | $114.86 | $29.06 |
| Average True Range (ATR) | 0.28 | 1.41 |
| MACD | -1.58 | 0.04 |
| Stochastic Oscillator | 83.08 | 24.02 |
Price Performance
Historical ComparisonAbout ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.